Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
- 2.8k Downloads
To assess safety and outcome of radiofrequency ablation (RFA) and microwave ablation (MWA) as compared to systemic chemotherapy and partial hepatectomy (PH) in the treatment of colorectal liver metastases (CRLM).
MEDLINE, Embase and the Cochrane Library were searched. Randomized trials and comparative observational studies with multivariate analysis and/or matching were included. Guidelines from National Guideline Clearinghouse and Guidelines International Network were assessed using the AGREE II instrument.
The search revealed 3530 records; 328 were selected for full-text review; 48 were included: 8 systematic reviews, 2 randomized studies, 26 comparative observational studies, 2 guideline-articles and 10 case series; in addition 13 guidelines were evaluated. Literature to assess the effectiveness of ablation was limited. RFA + systemic chemotherapy was superior to chemotherapy alone. PH was superior to RFA alone but not to RFA + PH or to MWA. Compared to PH, RFA showed fewer complications, MWA did not. Outcomes were subject to residual confounding since ablation was only employed for unresectable disease.
The results from the EORTC-CLOCC trial, the comparable survival for ablation + PH versus PH alone, the potential to induce long-term disease control and the low complication rate argue in favour of ablation over chemotherapy alone. Further randomized comparisons of ablation to current-day chemotherapy alone should therefore be considered unethical. Hence, the highest achievable level of evidence for unresectable CRLM seems reached. The apparent selection bias from previous studies and the superior safety profile mandate the setup of randomized controlled trials comparing ablation to surgery.
KeywordsColorectal liver metastases (CRLM) Radiofrequency ablation (RFA) Microwave ablation (MWA) Partial hepatectomy (PH) Systemic chemotherapy
American College of Radiology
Ablation-site recurrence rate
Colorectal liver metastases
European Society for Medical Oncology
Grading of Recommendations, Assessment, Development and Evaluation
Dutch Comprehensive Cancer Centre
Belgian Health Care Knowledge Center
Local progression-free survival
National comprehensive cancer network
National Institute for Health and Care Excellence
Optimal information size
Quality of life
Randomized controlled trial
Reduced relative risk
Scottish Intercollegiate Guidelines Network
Dutch National Health Care Institute
Colorectal cancer is the second most common cause of cancer-related death in developed countries and the third most common malignancy worldwide . Roughly 50% of patients develop colorectal liver metastases (CRLM), yet only a minority (10–15%) can undergo partial hepatectomy (PH). Five-year survival following PH ranges between 31 and 58% in carefully selected patients [2, 3]. The remainder is usually offered chemotherapy and/or local tumour ablation alone or in combination with PH. Especially radiofrequency (RFA) and microwave ablation (MWA) are commonly employed and widely available. Median overall survival (OS) following systemic treatment nowadays reaches 20–22 months in patients who receive sequential chemotherapy regimens often with biological agents; 5-year survival remains < 15% [4, 5, 6, 7, 8]. Five-year survival following ablation varies between 17 and 53% [9, 10, 11, 12, 13]. Although recent studies [13, 14, 15, 16] have reported similar survival for patients treated with thermal ablation or PH, interventional radiology and surgical oncology communities generally state that thermal ablation cannot be considered an alternative to PH. They recommend the use of open, laparoscopic or percutaneous RFA and MWA for small CRLM (≤ 3 cm) in patients who are unsuitable for resection due to (1) an impaired general health status (age, comorbidities), (2) a history of extensive abdominal surgery, (3) the presence of lesions with an unfavourable location or (4) an insufficient future liver remnant to resect all lesions [11, 17, 18]. In light of these recommendations the Dutch National Health Care Institute (ZiNL) and representatives from the Dutch societies for interventional radiology, surgical and medical oncology commissioned a systematic review and meta-analysis with the following research questions: (1) what is the evidence regarding safety and effectiveness for RFA and MWA in the treatment of CRLM? and (2) what is the status of RFA and MWA in international guidelines?
Materials and Methods
The search strategies and inclusion criteria were based on the following PICOS question: P (population): patients with resectable and unresectable CRLM; I (intervention): RFA and MWA; C (comparison): for resectable disease PH and for unresectable disease systemic chemotherapy; O (outcomes): critical endpoints were OS, complications and quality of life (QoL), important endpoints were disease-free survival (DFS), local progression-free survival (LPFS), and ablation-site recurrence rate (ASR); S (study designs): (systematic reviews), randomized studies, controlled studies, comparative observational studies with multivariate analysis and/or matching, non-comparative studies if an insufficient number of comparative studies was found. To assess the relative importance of outcomes (critical, important but not critical or limited) the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was used .
We used Cochrane systematic review methods to identify studies that met the inclusion criteria. MEDLINE, Embase and the Cochrane Library (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness, Health Technology Assessment database, CENTRAL) were searched (last update September 26th 2017) using a combination of text words and medical subheadings (search strategies: Table 3 online appendix). No time limit was used.
Searches were limited to studies involving humans and published in English or Dutch. Abstracts were only taken into consideration when their methodological quality could be sufficiently evaluated and data extraction could be entirely completed. Studies also describing primary liver tumours and/or non-colorectal liver metastases were only included if data about CRLM could be extracted separately. Only studies reporting on the following outcomes were considered: (1) critical outcomes: OS, QoL and complications; (2) important outcomes: DFS, LPFS, ASR.
Study Selection and Quality Criteria
All retrieved studies were evaluated for inclusion by two reviewers (JV, KHH) independently. First, studies were evaluated on title and abstract. Studies potentially eligible for inclusion were ordered in full text for a comprehensive evaluation.
For the included studies, the methodological quality was evaluated independently using the AMSTAR tool for systematic reviews and the risk of bias tool of the Cochrane Collaboration for randomized trials and controlled studies. For uncontrolled studies (including case series) the following criteria were judged: adequate definition of disease, clear baseline characteristics, inclusion of a representative cohort, adequate disease confirmation using validated methods, standardized data collection and objective outcome measurement.
All discrepancies were resolved by consensus. If no consensus was reached, the opinion of a third researcher (LGF) was the overriding factor.
Data were extracted by one reviewer (KHH or LGF) and checked by a second (JV). The results were displayed as described in the article, allowing for recalculations based on the data extracted from the article if needed.
Based on clinical criteria, such as population, intervention, control group and outcome, an assessment was made whether the studies were sufficiently comparable to perform a meta-analysis. A random effects model was chosen, unless there was no statistical heterogeneity. Individual results were presented in a forest plot. The following comparisons and outcomes allowed for a meta-analysis: (1) RFA versus PH alone regarding OS, DFS, LPFS, 30-day mortality and complications, and (2) RFA + PH versus PH alone regarding OS, DFS, LPFS and 60-day mortality. For time-to-event outcomes (survival), the generic inverse variance method was used. Only corrected hazard ratios (HR; e.g. based on a multivariate analysis) were imputed. For dichotomic results (complications), the Mantel–Haenszel method was used to calculate risk ratios (RR). When ≥ 10 studies were available for inclusion in the meta-analysis a funnel plot was used to assess for publication bias. The meta-analysis was conducted using Review Manager 5.3.
Levels of Evidence
RFA (± PH) + chemotherapy is superior to chemotherapy alone
1 RCT (downgraded; serious imprecision)a
RFA + chemotherapy is superior to chemotherapy alone
1 RCT (downgraded 2x; serious indirectnessb and serious imprecision)a
RFA (for unresectable CRLM) + PH is equivalent to PH alone
Observational comparative studies
RFA alone (for unresectable CRLM) is inferior to PH alone
Observational comparative studies
MWA is equivalent to PH
1 RCT (downgraded; very serious risk of bias)
MWA (for unresectable CRLM) + PH is equivalent to PH alone
One observational comparative study
RFA alone (for unresectable CRLM) is superior to PH
Observational comparative studies
Studies on RFA (for unresectable CRLM) + PH versus PH alone show conflicting results
Observational comparative studies
MWA alone is equivalent to PH
1 RCT (downgraded; very serious risk of bias)
Quality of life
There are no comparative studies on the effect of RFA or MWA
Two independent researchers graded the evidence levels (JV, KHH). If consensus was not reached, the opinion of a third independent researcher was decisive (LGF). The reasons for appointing evidence levels were documented.
(Inter)national guidelines about RFA and MWA for CRLM were searched in the following database: National Guideline Clearinghouse and Guidelines International Network as well as on websites of (inter)national guideline organizations and scientific societies. Two reviewers (JV, LGF) selected and judged the guidelines using the AGREE II instrument (Table 2 online appendix) . If consensus was not reached, the opinion of a third independent researcher (KHH) was decisive.
RFA Plus Chemotherapy Versus Chemotherapy Alone
The EORTC-CLOCC trial reported a 30-month OS of 61.7% (95% confidence interval (CI) 48.2–73.9%) for the combination group versus 57.6% (95%CI 44.1–70.4%) in the chemotherapy alone group . After a median follow-up of 9.7 years, OS was significantly better in the RFA + chemotherapy group (HR = 0.58; 95%CI 0.38–0.88) with an 8-year OS of 35.9 versus 8.9% for chemotherapy alone . In the RFA arm 27 out of 50 patients also underwent hepatic resection(s) which may have confounded results.
RFA Versus PH Alone
Five articles allowed for pooling of OS results for solitary metastases. Again, RFA was associated with a less favourable outcome (HR = 1.77; 95%CI 1.18–2.65) [31, 33, 34, 35, 39]. The corrected odds ratio as reported by Aloia et al. also showed better results for PH alone (odds ratio 3.22; 95%CI 1.74–5.96) .
RFA Plus PH Versus PH Alone
Adverse Events and Quality of Life
Ruers et al. reported the effect of RFA on quality of life using EORTC QLQ-C30 questionnaires . With 110 out of 119 patients included in the analysis, overall quality of life decreased 27 points on average after the procedure to partially restore (to 10 points under baseline) prior to starting chemotherapy (4–8 weeks after RFA) and completely restored hereafter. No formal statistical comparison was done.
Local Progression-Free Survival, Disease-Free Survival and Ablation-Site Recurrence
RFA Plus Chemotherapy Versus Chemotherapy Alone
Ruers et al. reported a significantly longer median DFS of 16.8 months (95%CI 11.7–22.1) in the combination group versus 9.9 months (95%CI 9.3–13.7) in the chemotherapy alone group corresponding to a HR of 0.63 (95%CI 0.42–0.95, p = 0.025) . The percentage of patients treated for the first progression was comparable between both arms, 37 out of 42 patients (88.1%) in the combination treatment group and 46 out of 53 patients (86.8%) in the systemic treatment group. The long-term results, confirmed an overall DFS favouring RFA + chemotherapy (HR 0.57; 95% CI 0.38–0.85; p = 0.005). The 8-year DFS for RFA + chemotherapy versus chemotherapy alone was 22.3% (95%CI 12.7–33.7) versus 2.0% (95%CI 0.2–9.0) .
RFA Versus PH Alone
RFA Plus PH Versus PH Alone
Shibata et al. reported a 3-year OS of 23% after hepatectomy and 14% after MWA . Median OS was 25 versus 27 months (p = 0.83).
Engstrand et al. reported a 4-year OS of 41% for the MWA group versus 4% in the historical cohort treated with chemotherapy alone . Treatment modality was found to be a prognostic factor in multivariate analysis (HR = 0.56; 95%CI 0.33–0.96). The 4-year OS in the PH alone cohort was 70%, but no formal statistical comparison was reported.
Tanaka et al. did not detect a significant difference in OS between MWA + PH versus PH alone (3-year OS: 50.9 vs. 48.8%) . Median OS was 39 months after PH and 28 months after MWA + PH. In multivariate analysis, MWA was no prognostic factor for OS.
Median OS in five case series ranged between 24 and 36 months [53, 54, 57, 58, 59]. The reported 3-,4- and 5-year OS varied between 35–79% [53, 54, 59, 60], 35–58% [52, 55] and 17–18% [53, 59], respectively.
Mortality, Adverse Events and Quality OF Life
Both Shibata et al. and Tanaka et al. did not detect any mortality after MWA or PH within 60 days after the procedure [48, 49]. Reported mortality in the case series ranged from 0 to 2% [55, 57, 59]. Shibata et al. reported complications in 2/14 patients in the MWA group (1 liver abscess, 1 biliary fistula) and in 3/16 in the PH group (1 intestinal obstruction, 1 biliary fistula, 1 wound infection) (p = 0.87) . Tanaka et al. found complications in 6/37 patients undergoing liver PH versus 3/16 in the combination group (no p = value reported) . In the case series, the documentation of complications was heterogeneous. Complication rates varied between 0 and 54% [51, 52, 54, 56, 57, 59]. No studies reported the effect on quality of life.
Disease-Free Survival and Ablation-Site Recurrence
Shibata et al. reported a median DFS of 13.3 months following PH versus 11.3 months following MWA . Tanaka et al. did not detect a significant difference in DFS (4-year DFS: 39 vs. 35%; p = 0.86) . After a median follow-up of 21 months, 28/34 (19 in the liver) patients in the PH group had a recurrence versus 11/15 (9 in the liver) in the MWA group after a median follow-up of 19 months.
Eng et al. reported a 3.5-year DFS of 19% . Stattner et al. found a 3-year DFS of 22% for the entire MWA group and 32% for the MWA alone subgroup . Two studies found a median DFS of 8 and 12 months [57, 59]. Groeschl et al. reported a 3- and 5-year DFS of 34 and 9%, respectively . In a second series Groeschl et al. found a 3-year DFS of 0% . Overall recurrence was present in 39–72% [52, 53, 54, 57, 59]. In 8 case series ASR varied between 2 and 30% [51, 52, 53, 54, 56, 57, 58, 59].
The search for guidelines resulted in 15 references, out of which two were excluded because they were updated by a more recent version [61, 62]. Thirteen references were evaluated based on their full text; all were included and assessed according to the AGREE II instrument (Table 2 online appendix) [63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75]. In 4 guidelines RFA and MWA was not mentioned [63, 64, 65, 66]. In 1 guideline RFA was mentioned but without clear recommendations . The American College of Radiology (ACR) guideline does not include specific recommendations, but RFA was described as unsuitable for CRLM, although scientific support for this statement is lacking . The US National Comprehensive Cancer Network (NCCN) guidelines do not provide well-defined recommendations for RFA and MWA, although they do write the following: “The panel does not consider ablation to be a substitute for resection in patients with completely resectable disease. In addition, resection or ablation (either alone or in combination with resection) should be reserved for patients with disease that is completely amenable to local therapy. Use of surgery, ablation, or the combination, with the goal of less-than-complete resection/ablation of all known sites of disease, is not recommended” [69, 70]. References to the EORTC-CLOCC trial and to several observational studies were used to support these statements [3, 29, 46, 76, 77, 78, 79, 80]. The European Society for Medical Oncology (ESMO) considers RFA suitable for CRLM < 4 cm if surgery is contra-indicated and refers to the EORTC-CLOCC trial and a systematic review [29, 71, 78]. The UK National Institute for Health and Care Excellence (NICE) guideline considers the current evidence on safety and efficacy adequate to support the use of this procedure in patients unfit or otherwise unsuitable for hepatic resection, or in those who have previously had hepatic resection, provided that normal arrangements are in place for clinical governance, consent and audit . The Scottish Intercollegiate Guidelines network (SIGN) commends that ablation should be considered for CRLM [73, 81]. The Belgian Health Care Knowledge Center (KCE) recommends the use of RFA in combination with PH to preserve sufficient future liver remnant and refers to the NICE, SIGN and CCO guidelines . The most comprehensive recommendations were reported in the Dutch Comprehensive Cancer Centre (IKNL) guideline: thermal ablation cannot be considered a substitute for resection, but represents a suitable treatment option for unresectable CRLM if the goal is a complete eradication of all lesions with curative intent . Percutaneous ablation can be considered for patients who are less suitable for surgery because of high-age, comorbidity, unfavourable location or a history of extensive abdominal surgery. The ablation technique of the first choice is RFA. MWA can be considered a good alternative, especially for lesions in proximity of large blood vessels where heatsink, when heat is carried away by the flowing blood, may enable tumour cells to survive after RFA. IKNL refers to the EORTC-CLOCC trial, the Cochrane review and several observational studies [3, 26, 29, 82, 83, 84, 85].
Contradictory to the many available comparative observational studies and case series on thermal ablation for CRLM, the literature to reliably assess its effectiveness compared to chemotherapy and surgery is limited. Although one RCT was identified for RFA , GRADE valuation required downgrading the quality of evidence regarding OS. When comparing RFA (± PH) + chemotherapy to chemotherapy alone, quality was downgraded to moderate, especially because both the optimal information size (OIS; number of included patients did not meet sample size) and the reduced relative risk (RRR = 100 * [1 − upper limit of the 95%CI for the HR (0.88)] = 12%) was too low (serious imprecision; Table 1). When comparing RFA + chemotherapy to chemotherapy alone, quality was further downgraded to low, because a substantial part of the ablated patients also underwent PH (serious indirectness). However, the remarkable differences in 8-year OS (8.9 vs. 35.9%) and 8-year DFS (22.3 vs. 2.0%) seem to validate the eradication of all macroscopically visible CRLM and to justify the adoption of thermal ablation for unresectable CRLM for this indication . The very serious risk of bias of the one MWA trial required downgrading to very low-quality evidence.
Comparing PH alone for resectable lesions with RFA for unresectable lesions, RFA was associated with significantly fewer complications but also with an inferior survival. In contrast, RFA in addition to PH for patients with unresectable disease, resulted in a comparable survival to resection alone for patients with resectable disease. In other words, for patients with unresectable disease, in whom palliative chemotherapy used to denote the only treatment option, RFA is able to offer patients a DFS and OS comparable to or approaching that of surgical candidates. Out of the eight studies published after 2012, seven showed a similar OS when comparing ablation (± PH) to PH alone (Figs. 5, 6), which may advert to ablative technique improvements. Although MWA compared to chemotherapy alone was associated with a superior OS for patients with unresectable CRLM, this is based on a single retrospective study at risk of bias due to the unclear randomization process, which seriously demotes quality of evidence .
In contrast to RFA, the number of comparative studies for MWA was limited. For this reason, we incorporated more restrictions for the RFA studies, including only RCTs and observational studies that performed either case matching or multivariate analysis for prognostic factors.
The included observational studies were by definition all confounded by indication, since ablation was only performed for unresectable lesions. Reasons for choosing ablation over PH were comorbidity (0–41%), inadequate future liver remnant and/or technical factors such as difficult anatomical location (5–67%), patient’s choice (0–61%) or extrahepatic disease for studies where this was no exclusion criterion (0–19%). Two other methods to adjust for confounding, namely restricting inclusion to patients from one prognostic category (for example bilobar CRLM) or stratification into subgroups were not allowed, because these methods only take one prognostic factor into account. All outcome measures were heterogeneously reported and follow-up periods ranged between 19 and 61 months in observational studies on RFA. The documentation of tumour load and disease status was strongly variable as were the definitions of progression-, recurrence- and disease-free survival.
The reporting of complications was heterogeneous, which is why it is difficult to identify the most frequent complications for thermal ablation. Of the 24 observational studies, only two were published prior to 2008. In recent years, several technical advancements were implemented in the field of RFA, although the same can be assumed for surgical techniques. The impact of these two older reports on the global results is probably limited. For MWA this effect may be greater, because the only RCT was published in 2000 and one of two observational studies in 2006. Although technical factors such as an unfavourable anatomical location were used to choose for thermal ablation, clear definitions for resectability were not provided in any of the included studies, with the exception of Ruers et al., who defined resectability as “the possibility to completely resect all CRLM” . For this reason, subgroup analysis was impossible and the risk for potential confounding by indication remains high. In the thermal ablation studies, the number of procedures necessary to reach local control was heterogeneously reported.
At the time of literature review, there was only one series comparing RFA to MWA for CRLM . Of 243 patients there were no differences regarding OS and ASR between RFA and MWA (p = 0.559 and 0.078, respectively), although the complication rate for peribiliary CRLM was higher after MWA (p = 0.002).
Conclusions drawn from previous meta-analyses are comparable to ours with regard to patients with resectable CRLM, but differ for patients with unresectable disease. The review from Sutherland et al.  (published in 2006) was probably too old to find sufficiently relevant studies. Belinson et al.  and Cirocchi et al.  concluded: “Evidence from the included studies are insufficient to recommend RFA for a radical oncological treatment of CRLMs”. Gurusamy et al. did not find any RCTs . Bala et al.  and Loveman et al.  found one RCT for MWA (Shibata et al.  published in 2000) and concluded: “Evidence is insufficient to show whether microwave coagulation brings any significant benefit in terms of survival or recurrence compared with conventional surgery for CRLM patients”. Smith et al.  did not assess RFA separately. Pathak et al.  were more positive in their conclusions, although their analysis primarily included case series.
The results from this analysis should be judged with caution. Although systematically obtained, there are no guarantees that all available evidence was identified. Furthermore, the inclusion of observational studies increases the risk for publication bias, for which objective indications were detected for the complication rate. Although (for RFA) only studies using randomization, matching or multivariate analysis was included, this does not exclude residual confounding.
To conclude, this article is the first systematic review that supports the widespread adoption of thermal ablation to treat small unresectable CRLM. The (1) recently published long-term survival results from the EORTC-CLOCC trial , the (2) comparable survival results after ablation versus resection for the series reported after 2012, the (3) comparable survival after ablation + resection versus resection alone, the (4) potential to induce long-term disease control and the (5) low complication rates all argue in favour of thermal ablation over chemotherapy alone. Further randomized comparisons of thermal ablation with curative intent to current-day palliative chemotherapy alone should therefore be considered unethical. As a consequence, the highest achievable evidence level for unresectable CRLM seems to have been reached.
Although ablation for unresectable CRLM seems inferior to PH for resectable lesions, the lower complication rate combined with the apparent selection bias stresses the need to conduct a randomized controlled trial. Currently, PH for resectable CRLM is being challenged by thermal ablation in a large multicentre, phase III, randomized controlled trial (COLLISION trial; NCT03088150). This study assesses overall- and disease-free survival, time to (local) progression, primary and assisted technique efficacy rates, adverse events, quality of life and incremental costs.
Compliance with Ethical Standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- 1.Bala MM, Riemsma RP, Wolff R, Kleijnen J. Microwave coagulation for liver metastases. Cochrane Database Syst Rev. 2013;(10):CD010163.Google Scholar
- 2.Belinson S, Chopra R, Yang Y, Shankaran V, Aronson N. Local hepatic therapies for metastases to the liver from unresectable colorectal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012:13-EHC014-EF.Google Scholar
- 3.Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;6:CD006317.Google Scholar
- 4.Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2000;11(11):1477–83.CrossRefPubMedGoogle Scholar
- 9.Gurusamy KS, Ramamoorthy R, Imber C, Davidson BR. Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases. Cochrane Database Syst Rev. 2010;(1):CD006797.Google Scholar
- 19.Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. Update October 2013. www.gradeworkinggroup.org. Accessed 26 Sept 2017.
- 22.Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument. AGREE Next Steps Consortium. www.agreetrust.org. Accessed 26 Sept 2017.
- 23.Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess. 2014;18(7):vii–viii, 1–283.Google Scholar
- 61.Comprehensive Cancer Organisation the Netherlands (I.K.N.L.). National evidence-based guideline. Colorectal liver metastases. http://www.oncoline.nl/colorectale-levermetastasen (2006). Accessed 26 Sept 2017.
- 62.Comprehensive Cancer Organisation the Netherlands (I.K.N.L.). National evidence-based guideline. Rectumcarcinoom. http://www.oncoline.nl/rectumcarcinoom (2008). Accessed 26 Sept 2017.
- 66.Gallinger S, Biagi JJ, Fletcher GG, Nhan C, Ruo L, McLeod RS. The role of liver resection in colorectal cancer metastases. Toronto: Cancer Care Ontario (CCO). http://www.guideline.gov/content.aspx?id=45892 (2012). Accessed 26 Sept 2017.
- 68.Reston V. American College of Radiology (A.C.R.). Appropriateness criteria. Rectal cancer—metastatic disease at presentation. http://www.guideline.gov/content.aspx?id=48299 (2014). Accessed 26 Sept 2017.
- 69.National Comprehensive Cancer Network (N.C.C.N.). Guidelines. Colon cancer. Version 3. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2015). Accessed 26 Sept 2017.
- 70.National Comprehensive Cancer Network (N.C.C.N.). Guidelines. Rectal cancer. Version 3. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2015). Accessed 26 Sept 2017.
- 72.National Collaborating Centre for Cancer (N.I.C.E.). Guidelines. Radiofrequency ablation for colorectal liver metastases. https://www.nice.org.uk/guidance/ipg327 (2009). Accessed 26 Sept 2017.
- 73.Scottish Intercollegiate Guidelines Network (S.I.G.N.). Diagnosis and management of colorectal cancer. A national clinical guideline. http://www.guideline.gov/content.aspx?id=35211 (2011). Accessed 26 Sept 2017.
- 74.Peeters L, Leroy R, Robays J, Veereman G, Bielen D, Ceelen W. Belgian Health Care Knowledge Center (K.C.E.). Colon cancer: diagnosis, treatment and follow-up. http://kce.fgov.be/publication/report/colon-cancer-diagnosis-treatment-and-follow-up (2014). Accessed 26 Sept 2017.
- 75.Comprehensive Cancer Organisation the Netherlands (I.K.N.L.). National evidence-based guideline. Colorectaal carcinoom. http://oncoline.nl/ (2014). Accessed 26 Sept 2017.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.